The aptamers market is estimated to be worth $451 million in 2024, driven by launch of Izervay and is expected to grow at compounded annual growth rate (CAGR) of 36% during the forecast period 2024-2035. Aptamer technology and services market is estimated to be $58 million in 2022, growing at double-digit CAGR consistent with the market trends in aptamer therapeutics. Post the approval of the first aptamer-based therapy, Macugen®, by the US Food and Drug Administration (USFDA) in December 2004, there has been a significant increase in the R&D initiatives focused on evaluating the potential of aptamers as theranostic agents.

1. Tracking the healthcare innovation
Free Insights
Aptamers: Therapeutics, Technologies and Services Market,
2022-2035
Distribution by [A] Application Area (Therapeutics, Research and Diagnostics), [B] Type of Aptamer (DNA, RNA and Peptide), [C]
Target Indications (Brain Cancer, Geographic Atrophy, Hemophilia A, Macular Degeneration, Pancreatic Cancer, Von Willebrand
Diseases), [D] Route of Administration (Intravitreal, Intravenous, Subcutaneous), [E] Scale of Operation (Small Scale, Medium Scale
and Large Scale), [F] Focus Area (Product Development, Product Commercialization, Technology Integration, Technology
Utilization and Others), [G] Company Size (Very Small, Small, Mid-sized, Large and Very Large) and [H] Key Geographical Regions
(North America, Europe, Asia-Pacific and Rest of the World)
C O N F I D E N T I A L | www.rootsanalysis.com

2. 2
2022 © Roots Analysis
Upon realizing the potential of aptamers over antibodies, industry stakeholders have initiated several R&D efforts focused on exploiting
the use of aptamers for various purposes such as detection, diagnosis, treatment and research
Driven by encouraging clinical trial results
and the growing demand for safe and cost-
effective treatments, along with
development of novel technologies, the
aptamers market is anticipated to witness
accelerated growth, over the next decade
Aptamers have recently emerged as a
promising target for the development of
various therapies; several candidates in the
development pipeline have demonstrated
considerable benefits over conventional
antibody-based treatment methods
Given the various advantages offered by this
novel drug class, the demand for aptamer-
based therapeutics is expected to witness a
notable surge, presenting lucrative
opportunities for contract services providers
in the coming decade
Current Industry
Landscape and
Upcoming Trends
Indicative of the high
growth opportunity in
the aptamer-based
therapeutics market
Has been invested to
finance R&D efforts
in this domain, over
the last few years
Currently being
developed for a
range of application
areas
40+ Drug
Candidates >450
Overview of
Aptamers
Market
Filed by various
industry and non-
industry stakeholders
since 2016
Currently being
evaluated across
various stages of
development
Non-immunogenic
Targets
Aptamer synthesis
does not involve
living cells, allowing
for their use against
toxic compounds
Advantages of
Aptamers Over
Antibodies
Enables targeting
molecules that are
ten times smaller
than those targeted
by antibodies
Targets
Small Molecules
Stability and
Storage
These molecules can
be stored easily, as
they are resistant to
denaturation at high
temperatures
Have required
capabilities to cater
to the needs of drug
developers
Patents
50+ Aptamer
Technologies 1.3+ >25% CAGR
USD
Billion
50+ Service
Providers
Context

3. 3
2022 © Roots Analysis
Note 1: Macugen was approved by the United States Food and Drug Administration in December 2004
Note 2: Players were categorized based on company size (in terms of number of employees) as : Very Small: 2-10, Small:11-50, Mid-sized: 51-200, Large: 201-5,000, Very Large: 5,000+
S.No Drug Company
Phase of
Development
Type of Aptamer Target Indication Therapeutic Area
Route of
Administration
Mechanism of Action
Line of
Treatment
Type of Therapy Trial ID
1 Drug 1 Company 1 Approved RNA
Macular
Degeneration
Opthalmological
Disorders
Intravitreal VEGF antagonist ≥2 Monotherapy NCT00324116
9 ZimuraTM
Company 2 Phase III RNA
Geographic
Atrophy, Macular
Degeneration
Opthalmological
Disorders
Intravitreal Inhibits Complement C5 ≥1 Monotherapy NCT04435366
15 Drug 15 Company 15 Phase II L-RNA Multiple Myeloma
Oncological
Disorders
Intravenous CXCL12 antagonist ≥2 P NCT01521533
23 BC 007 Berlin Cures Phase II DNA
Cardiomyopathy,
Heart Failure,
Autoantibodies
Cardiovascular
Disorders,
Immunological
Disorders
Intravenous
Virus replication
inhibitors, GPCR-
autoantibodies
Neutralizer
≥1 P NCT04192214
30 Drug 30 Company 3 Phase I / II RNA Ischemic Stroke
Neurological
Disorders
Intravenous
Antagonize TLR4
Receptor
P NCT04734548
35 RBM-007 Phase I / II RNA
Age Related
Macular
Degeneration
Opthalmological
Disorders
Intravitreal
Fibroblast growth factor
inhibitors
≥1 NCT04895293
40 Drug 40 Company 4cs Phase I DNA
Advanced Solid
Tumors
Oncological
Disorders
Intravenous Nucleolin inhibitors P NCT00881244
42 DTRI-0031
Basking
Biosciences
Phase I RNA Ischemic Stroke
Neurological
Disorders
Intravenous
Von Willebrand Factor
Inhibitors
P NCT05005520
List of Aptamer-based Therapeutic Candidates1
Example Highlights
Presently, more than 40 aptamer-based drug candidates are being investigated across different phases of
development for the treatment of a myriad of disease indications
Developer Landscape: Distribution by Company Size and Location of Headquarters2
56%
31%
13%
Asia-Pacific
Europe
North America
Full list of 40+ aptamer-based
therapies, along with information on
several parameters is available in an
excel format upon request
31%
37%
13%
6%
13%
Very Small Small Mid-sized
Large Very Large

4. 4
2022 © Roots Analysis
Example Highlights
Most of the aptamer drugs are being developed as RNA-based therapies; 46% of the aptamer-based therapies
are in pre-clinical stage and are being developed for various therapeutic areas
Market Landscape: Aptamer-
based Therapy Candidates
Distribution by Type of Aptamer1
Market Landscape: Aptamer-
based Therapy Candidates
Distribution by Phase of Development2
Market Landscape: Aptamer-
based Therapy Candidates
Distribution by Therapeutic Area3,4
12
7
4
3
3
2
2
1
1
1
1
1
1
Oncological Disorders
Cardiovascular Disorders
Opthalmological Disorders
Hematological Disorders
Neurological Disorders
Bone Disorders
Metabolic Disorders
Bleeding Disorders
Gastrointestinal Disorders
Genetic Disorders
Infectious Diseases
Inflammatory Disorders
Immunological Disorders
Note 1: Therapies for which information on type of aptamer was available have been included in this representation
Note 2: Therapies for which information on phase of development was available have been included in this representation
Note 3: Therapies for which information on therapeutic area was available have been included in this representation
Note 4: Therapies targeting more than one therapeutic area have been counted multiple times in this representation
3%
2%
24%
5%
5%
46%
15%
Approved Phase III Phase II
Phase I / II Phase I Pre-Clinical
Discovery
61% 24%
11% 4%
L-RNA
Aptamers
Peptide
Aptamers
RNA
Aptamers
DNA
Aptamers

5. 5
2022 © Roots Analysis
Example Highlights
Foreseeing lucrative returns, many public and private investors have made investments worth USD 1.3 billion
since 2016; the funding activity is well distributed across geographical regions
Fundings and Investments
Cumulative Distribution of Instances
Funding and Investments
Distribution by Amount Invested and ToF2
Funding and Investments
Distribution by Amount Invested and LoR
USD 442 Million
Invested in 2021
USD Million
1.3+ USD Billion Invested
28%
Funding
instances in
North America
41%
Funding
instances in
Europe
31%
Funding
instances in
Asia-Pacific
Abbreviations: FI: Funding Instances; ToF: Type of Funding; LoR: Location of Recipient
Example Investors
60+
Investors
2021
2020
2019
2018
2017
2016
XX
XX
XX
60.5
XX
XX
XX
43
XX
XX
8.4
XX
54.7
XX
XX
XX
XX
XX
XX
5.2
XX
7.3
XX
Legend
Seed Financing
Debt Financing
Venture Capital
Private Placement
Awards / Grants
Secondary Offering
Other Equity
Others
10
13
34
38
60
71
233
485 487
913
2016 2017 2018 2019 2020 2021
Cummulative Instances
Cummulative Amount Invested

6. 6
2022 © Roots Analysis
Example Highlights
A considerable increase in partnership activity has been witnessed over the past few years, indicating a steady
rise in the interest of stakeholders
Partnerships and Collaborations
Year-wise Trend, 2016-20211,2
Partnerships and Collaborations
Distribution by Type of Partnerships2
Partnerships and Collaborations
Country-wise Distribution2
Type of Partnerships in 2021:
36% 23% 29%
Research and
Development
Agreements
Product
Development
Agreements
Service
Agreements
XX
13
9
XX
XX
XX
2016 2017 2018 2019 2020 2021
CAGR: 20% (2016-2021)
34%
16%
12%
9%
7%
6%
4%
3%
9%
R & D Agreement
Product Development Agreement
Service Agreement
Merger and Acquistions
Product Development and Commercialization Agreement
Technology Licensing Agreement
Clinical Trial Agreement
Supply Agreement
Others
Example Partnership:
Note 1: 98 instances for which information on year of partnership was available have been included in this representation
Note 2: Information in this report (specifically this table) has been identified from publicly available sources on a ‘best-effort’ basis. However, we realize that some of the data points may not be publicly available, and as such, may have been
overlooked in our analysis. If you would like to notify us of these gaps, please send an email to support@rootsanalysis.com.
s
s
s
s
s
s
s
s
s
XX
7
8
1
2
1
2
1
XX
XX
X
4
X
2
International Agreement
Local Agreement
R & D Agreement
As per the terms of the
agreement, both firms agreed to
combine their technologies for
the discovery and development of
novel aptamer therapeutics
Focus Area
October 2021

7. 7
2022 © Roots Analysis
Start-up Health Indexing: Technology Providers
Stat-up Benchmarking1
Start-up Health Indexing: Technology Providers
Wind Rose Chart: Top 9 Players
Start-ups are spearheading the innovation in this domain; our proprietary benchmarking analysis, based on a
variety of parameters, highlights the leading players
P4
P1 P2 P3 P5 P6
Total
Score
Company
Developer 1
Developer 3
Developer 5
Developer 7
Developer 15
Developer 16
Developer 14
Developer 13
Developer 12
Developer 10
Developer 8
Note 1: Parameters considered for this analysis includes P1: Number of technologies, P2: Type of Aptamer, P3: Status of Development, P4: Ara of Application, P5: Types of Bioanalytical Technology Used, P6: Technology Application Area
Note 2: Start-ups for which information on company size was available have been included in this representation
Content Illustrative
(details available upon request)
Example Highlights
Company 1
Company 2
Company 3
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Score
Average
Score
~45.5% Aptamer-based technology developers are located in
North America
4
1
4
4
1 1 1
2 2
1
North America Europe Asia-Pacific Latin America
43%
33%
24%
Distribution by Company Size and Location of Headquarters 2
Very Small Small Mid-sized
Very Small
Small
Mid-sized

8. 8
2022 © Roots Analysis
Example Highlights
400+ academic grants have been awarded to organizations over the past five years to support the ongoing
efforts related to research and innovation in the field of aptamers
Note 1: 424 instances have been included in this representation
Note 2: The data has been collected through publicly available sources
Note 3: Others category includes activity codes for which specific information was not available
Note 4: Support period refers to the duration (calculated as the difference between start year and end year) for which a particular grant was awarded to a research institute / academic research group
Note 5: The representation highlights the keywords that appeared most frequently in the grants captured during our analysis
62
XX
XX
266
XX
XX
2016 2017 2018 2019 2020 2021
75%
2%
7%
16%
Research Grants (R series)
Research Training and Fellowships (T & F series)
Program Project/Center Grants (P series)
Others
Academic Grant Analysis
Cumulative Year-wise Trend1,2
Academic Grant Analysis
Word Cloud: NIH Spending Category5
Academic Grant Analysis
Distribution by Activity Codes1,2,3
USD 44 Million
24.3% granted in the year 2021
20 181
137
107
75
47
93%
3%
3%
1%
1-10 Years 11-20 Years
21-30 Years 31-40 Years
Academic Grants: Distribution by
Support Period4
Program Project / Center Grants (P Series)
USD Million
Cumulative Distribution of Grant Amount

9. 9
2022 © Roots Analysis
Roots Analysis
Contact Us
USA
sales-us@rootsanalysis.com
+1 (415) 800 3415
Europe
sales-eu@rootsanalysis.com
+44 (122) 391 1091
Asia-Pacific
sales-apac@rootsanalysis.com
+91 987 222 4848
FOLLOW US
Syndicated / Published Reports
 Pharmaceuticals / Biologics
 Medical Devices
 Diagnostics / Medical Imaging
 Clinical Research / Trials
 Drug Development / Delivery
 NextGen Technologies
 Contract Manufacturing
 Health and Wellness
 Packaging
 Nutraceuticals
 Healthcare IT
The leading research house for professionals, analysts and researchers for unbiased and insightful opinions in
the pharma / biotech domain
Consulting Portfolio
 Pipeline Tracking
 Market Assessment
 Therapy Area Assessment
 Clinical Trial Tracking
 KOL Selection
 Market Entry Strategies
 Unmet Need Analysis
 Publication Analysis
 Investment Analysis
 Deal Tracking
 Commercial Strategy & Business
Development
Australia
Canada
Germany
Italy
Japan
Netherlands
South Korea
Switzerland
UK
US
Belgium
China
France
India
20+ more client locations
Taiwan
Spain